Janssen Cilag Ltd

Lobbying Organisation Janssen Cilag Ltd

Date published 19 Jan, 2018

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 Sep, 2017 to 31 Dec, 2017

Specific Details The Framework Agreement on Medicine Pricing

Intended results To update Department of Health on the delay in the process of the reimbursement of new medicines

Name of person primarily responsible for lobbying on this activity Conor Sweeney

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Meeting with Jim Breslin to discuss the current delays being experienced by the industry in the reimbursement of new medicines. Raised the importance of having an efficient and sustainable system in place that ensures patients can access the most innovative medicines as quickly as possible. We also discussed the importance of the system being fully transparent around timelines for the reimbursement of new medicines.

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Jim Breslin Secretary General (Department of Health)